Objective To analyze the correlation between the pulmonary immune prognostic index (LIPI) and the prognosis of patients with advanced non-small cell lung cancer (NSCLC) treated with sintilimab.

Methods A total of 145 patients with advanced NSCLC were selected as study subjects. All patients received treatment with sintilimab, and their clinical baseline data were recorded. According to the LIPI score, patients were divided into low-risk, intermediate-risk, and high-risk groups. The correlation between LIPI and the prognosis of advanced NSCLC patients was analyzed. Factors influencing progression-free survival (PFS) and overall survival (OS) were identified.

Results Univariate analysis showed that patient age, smoking status, pathological type, clinical stage and LIPI were factors affecting PFS (P < 0.05); age, pathological type, clinical stage and LIPI were factors affecting OS (P < 0.05). Multivariate Logistic regression analysis revealed that age of 60 to 70 years, age > 70 years, adenocarcinoma, stage Ⅳ and high-risk LIPI were independent prognostic factors of PFS (P < 0.05); age > 70 years, poor stage Ⅳ, adenocarcinoma and high-risk LIPI were independent prognostic factors of OS (P < 0.05). LIPI influenced patient's prognosis, with low-risk patients showing better outcomes and longer median PFS and OS.

Conclusion LIPI is correlated with the prognosis of advanced NSCLC patients treated with sintilimab. Patients with a low-risk LIPI assessment benefit more from sintilimab treatment.